Neurocrine/$NBIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neurocrine
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Ticker
$NBIX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,800
ISIN
US64125C1099
Website
Neurocrine Metrics
BasicAdvanced
$13B
43.05
$2.96
0.26
-
Price and volume
Market cap
$13B
Beta
0.26
52-week high
$157.98
52-week low
$84.23
Average daily volume
1.2M
Financial strength
Current ratio
3.132
Quick ratio
1.804
Long term debt to equity
17.648
Total debt to equity
17.648
Profitability
EBITDA (TTM)
529.9
Gross margin (TTM)
63.91%
Net profit margin (TTM)
12.68%
Operating margin (TTM)
20.78%
Effective tax rate (TTM)
34.41%
Revenue per employee (TTM)
$1,340,000
Management effectiveness
Return on assets (TTM)
8.75%
Return on equity (TTM)
12.43%
Valuation
Price to earnings (TTM)
43.049
Price to revenue (TTM)
5.297
Price to book
4.97
Price to tangible book (TTM)
5.04
Price to free cash flow (TTM)
25.962
Free cash flow yield (TTM)
3.85%
Free cash flow per share (TTM)
490.36%
Growth
Revenue change (TTM)
21.73%
Earnings per share change (TTM)
-17.91%
3-year revenue growth (CAGR)
25.95%
10-year revenue growth (CAGR)
61.68%
3-year earnings per share growth (CAGR)
59.44%
10-year earnings per share growth (CAGR)
16.41%
What the Analysts think about Neurocrine
Analyst ratings (Buy, Hold, Sell) for Neurocrine stock.
Bulls say / Bears say
Neurocrine Biosciences reported a 23% year-over-year increase in INGREZZA® net product sales for Q4 2024, reaching $615 million, indicating strong market demand and effective commercialization strategies. (nasdaq.com)
The FDA approved the granule formulation of INGREZZA® in April 2024, expanding treatment options for patients with movement disorders associated with Huntington's disease, potentially increasing the drug's market penetration. (reuters.com)
Analysts project INGREZZA® could achieve $3.2 billion in U.S. sales by 2028, reflecting confidence in the drug's growth trajectory and market potential. (reuters.com)
The CEO and a director of Neurocrine Biosciences sold significant amounts of company stock in February 2025, which can be perceived as a lack of confidence in the company's near-term prospects. (investing.com, investing.com)
The company's stock declined over 22% in the week leading up to February 12, 2025, trading near its 52-week low of $110.95, indicating potential investor concerns about future performance. (investing.com)
Analysts have lowered price targets for Neurocrine Biosciences, with UBS reducing its target to $154 and Guggenheim to $163, reflecting tempered expectations for the company's stock performance. (investing.com, investing.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Neurocrine Financial Performance
Revenues and expenses
Neurocrine Earnings Performance
Company profitability
Neurocrine News
AllArticlesVideos
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
GlobeNewsWire·3 weeks ago
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
GlobeNewsWire·3 weeks ago
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neurocrine stock?
Neurocrine (NBIX) has a market cap of $13B as of June 20, 2025.
What is the P/E ratio for Neurocrine stock?
The price to earnings (P/E) ratio for Neurocrine (NBIX) stock is 43.05 as of June 20, 2025.
Does Neurocrine stock pay dividends?
No, Neurocrine (NBIX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Neurocrine dividend payment date?
Neurocrine (NBIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurocrine?
Neurocrine (NBIX) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.